Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056368 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
NCT00056368: Completed Phase 3 study, sponsored by Pfizer.
NCT00056368 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 256 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00056368, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
Study Summary
Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.
Interventions
- DRUG Fluconazole
- DRUG Anidulafungin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
What the finished NCT00056368 record still lists
NCT00056368 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which Fluconazole is the first listed.
NCT00056368 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00056368 about?
NCT00056368 is a clinical study titled "The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis". Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.
What is the current status of trial NCT00056368?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2003-03. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00056368?
The interventions under investigation include: Fluconazole (DRUG), Anidulafungin (DRUG).
Who is sponsoring clinical trial NCT00056368?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00056368's enrollment target sits among peer trials
256 1240th of 2000 higher than 759 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia